Home » Newsletters » BioWorld Science

BioWorld Science

May 18, 2009

View Archived Issues

Agile's low-dose levonorgestrel/ethinylestradiol contraceptive patch shows safety and efficacy

Positive clinical results reported for Archimedes' NasalFent fentanyl nasal spray for cancer pain

Novel c-Met and Ron kinase inhibitor, MK-8033, shows antitumor activity in preclinical studies

Clofarabine prodrug active in various tumor models

Heat shock protein 90 inhibitor CUDC-305 shows potent and lasting in vivo antitumor activity

Boehringer and DeveloGen sign agreement in diabetes, obesity and the metabolic syndrome

Bayer Schering launches oral contraceptive Qlaira in Europe

FDA approves Novartis' Prevacid 24HR for frequent heartburn

Allergan claims novel sphingosine 1-phosphate receptor ligands for the treatment of pain

Cardioxyl Pharmaceuticals and Johns Hopkins University claim novel compounds for heart failure

Boehringer Ingelheim reports discovery of chemokine CCR10 receptor antagonists as antipsoriatics

Polo-like kinase 1 inhibitors for cancer treatment presented by Nerviano Medical Sciences

CMV DNA vaccine may control post-transplant CMV viremia; interim phase II data disclosed

ImmuneRegen and University of Pittsburgh sign agreement for influenza drug Viprovex

FDA approves ActoGeniX's IND for phase Ib clinical trial of AG-013 in oral mucositis

DCGI grants approval to Piramal Life to initiate two phase I/II studies of cancer drug P-276

Oxygen Biotherapeutics signs LP-CRADA with NMRC and WRAIR for Oxycyte

Amgen presents Q1 product and pipeline update

Ablynx receives orphan drug designation and provides pipeline update

Intravitreal IBI-20089 reduces retinal thickness in cystoid macular edema patients in phase I trial

AGI releases results from phase III Rezular trial, plans to cease development in IBS-D

Nonsteroidal antiandrogen shows efficacy in castration-resistant prostate cancer in phase I/II trial

Antares presents preliminary phase II transdermal contraception results

Metabolic Solutions presents preliminary results from phase IIa MSDC-0160 trial

Novavax completes enrollment in second phase II seasonal influenza vaccine trial

Data show cardiovascular therapeutic potential for two Compugen peptides

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...